. Author manuscript; available in PMC: 2024 Oct 1.

Published in final edited form as: Lancet Child Adolesc Health. 2023 Aug 24;7(10):708–717. doi: 10.1016/S2352-4642(23)00174-8

Table 4:

Multivariable analysis of potential predictors of infant TST positivity at 44 weeks (n=727)

	TST result^*		Multivariable model
	Positive (n=55)	Negative (n=672)	Adjusted OR (95% CI)	p value
Maternal study group
Immediate isoniazid	29 (53%)	329 (49%)	1·26 (0·70–2·30)	0·44
Deferred isoniazid	26 (47%)	343 (51%)	1 (ref)	..
Maternal CD4 count at entry, cells per mm³	610·5 (276·5)	511·5 (235·1)	1·11 (0·99–1·25)	0·08
Maternal TST positive at delivery (up to 6 weeks postpartum)^†	17 (31%)	80 (11·9%)	3·28 (1·70–6·33)	0·0004
Infant BCG scar present^†	51 (93%)	535 (80%)	4·97 (1·50–16·43)	0·009
Exclusive breastfeeding for any duration	53 (96%)	528 (79%)	6·63 (1·57–27·92)	0·010

Data are n (%) or mean (SD). OR indicates likelihood of TST positivity. BCG=Bacille Calmette-Guérin. TST=tuberculin skin test. OR=odds ratio.

TST positivity was defined as induration diameter ≥5 mm for infants with HIV and ≥10 mm for infants without HIV.

^†

Only includes mother–infant pairs for whom data were available.